These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 32711786)

  • 21. Therapeutic drug monitoring for sofosbuvir and daclatasvir in transplant recipients with chronic hepatitis C and advanced renal disease.
    Vionnet J; Saouli AC; Pascual M; Stucker F; Decosterd LA; Moradpour D; Chtioui H
    J Hepatol; 2016 Nov; 65(5):1063-1065. PubMed ID: 27469899
    [No Abstract]   [Full Text] [Related]  

  • 22. Two Antiviral Drugs Approved For Adolescents With HCV.
    Aschenbrenner DS
    Am J Nurs; 2017 Aug; 117(8):22. PubMed ID: 28749879
    [No Abstract]   [Full Text] [Related]  

  • 23. High sustained virologic response rate using generic directly acting antivirals in the treatment of chronic hepatitis C virus Egyptian patients: single-center experience.
    El-Nahaas SM; Fouad R; Elsharkawy A; Khairy M; Elhossary W; Anwar I; Abdellatif Z; Maher RM; Bekheet N; Esmat G
    Eur J Gastroenterol Hepatol; 2018 Oct; 30(10):1194-1199. PubMed ID: 30096091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatitis C virus genotype 3: Meta-analysis on sustained virologic response rates with currently available treatment options.
    Ampuero J; Reddy KR; Romero-Gomez M
    World J Gastroenterol; 2016 Jun; 22(22):5285-92. PubMed ID: 27298572
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sofosbuvir-Daclatasvir-Simeprevir Plus Ribavirin in Direct-Acting Antiviral-Experienced Patients With Hepatitis C.
    Hézode C; Fourati S; Chevaliez S; Scoazec G; Soulier A; Varaut A; François M; Ruiz I; Roudot-Thoraval F; Mallat A; Pawlotsky JM
    Clin Infect Dis; 2017 Jun; 64(11):1615-1618. PubMed ID: 28369411
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sofosbuvir and Simeprevir for Treatment of Recurrent Hepatitis C Infection After Liver Transplant.
    Nair S; Satapathy SK; Gonzalez HC
    Exp Clin Transplant; 2017 Jun; 15(3):314-319. PubMed ID: 26926117
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatotoxicity and virological breakthrough of HCV following treatment with sofosbuvir, daclatasvir, and ribavirin in patients previously treated for tuberculosis.
    Wahid B
    J Med Virol; 2019 Dec; 91(12):2195-2197. PubMed ID: 31347729
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatitis C Virus Genotype 8 Infection-Successful Treatment With Sofosbuvir/Velpatasvir.
    Douglas MW; Tay ES; Eden JS; George J
    J Infect Dis; 2019 Jul; 220(4):720-722. PubMed ID: 30958539
    [No Abstract]   [Full Text] [Related]  

  • 29. [Progress of antiviral therapy for hepatitis C virus-related decompensated cirrhosis].
    Nan YM; Liu LD; Zhao W; Cui LY
    Zhonghua Gan Zang Bing Za Zhi; 2019 Dec; 27(12):919-922. PubMed ID: 31941253
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: A real-life observational study.
    Zeng QL; Xu GH; Zhang JY; Li W; Zhang DW; Li ZQ; Liang HX; Li CX; Yu ZJ
    J Hepatol; 2017 Jun; 66(6):1123-1129. PubMed ID: 28189754
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of a patient with genotype 7 hepatitis C virus infection with sofosbuvir and velpatasvir.
    Schreiber J; McNally J; Chodavarapu K; Svarovskaia E; Moreno C
    Hepatology; 2016 Sep; 64(3):983-5. PubMed ID: 27177605
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical decompensation after achieving SVR with sofosbuvir, daclatasvir and ribavirin in a patient with recurrent HCV post-liver transplant.
    Kalafateli M; Dusheiko G; Manousou P
    J Gastrointestin Liver Dis; 2015 Jun; 24(2):257-8. PubMed ID: 26114189
    [No Abstract]   [Full Text] [Related]  

  • 33. CROI 2015: Highlights of Viral Hepatitis Therapy.
    Luetkemeyer AF; Wyles DL
    Top Antivir Med; 2015; 23(1):66-76. PubMed ID: 25965313
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Severe Cholestatic Hepatitis C in Transplant Recipients: No Longer a Threat to Graft Survival.
    Giard JM; Terrault NA
    Clin Gastroenterol Hepatol; 2015 Nov; 13(11):2002-4. PubMed ID: 26192143
    [No Abstract]   [Full Text] [Related]  

  • 35. Changing the face of hepatitis C management - the design and development of sofosbuvir.
    Noell BC; Besur SV; deLemos AS
    Drug Des Devel Ther; 2015; 9():2367-74. PubMed ID: 25987834
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatitis C virus therapies.
    Smith RE
    Nat Rev Drug Discov; 2006 Sep; 5(9):715-6. PubMed ID: 17001802
    [No Abstract]   [Full Text] [Related]  

  • 37. Successful treatment of HCV-related glomerulonephritis with sofosbuvir and daclatasvir.
    Chia XX; Cherepanoff S; Danta M; Furlong T
    Nephrology (Carlton); 2018 Apr; 23(4):379-380. PubMed ID: 29520905
    [No Abstract]   [Full Text] [Related]  

  • 38. Brazil's Fight against Hepatitis C - Universalism, Local Production, and Patents.
    da Fonseca EM; Shadlen K; Bastos FI
    N Engl J Med; 2019 Feb; 380(7):605-607. PubMed ID: 30763192
    [No Abstract]   [Full Text] [Related]  

  • 39. Daclatasvir (Daklinza) for HCV genotype 3 infection.
    Med Lett Drugs Ther; 2015 Oct; 57(1479):142-3. PubMed ID: 26445205
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sofosbuvir/Velpatasvir (Epclusa) for Hepatitis C.
    Sokol R
    Am Fam Physician; 2017 May; 95(10):664-666. PubMed ID: 28671408
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.